CDK2 and neoplasm: Additionally, during dose escalation, PF-06873600 was investigated in tumor types that have the potential for increased cyclin E expression and/or CDK2 activity, including locally recurrent/advanced or metastatic triple-negative breast cancer (TNBC) and advanced platinum-resistant ovarian cancer.